n = 11,950 | DVTb
| PEb
| OTEb
|
|---|
| | HR (95% CI) | HR (95% CI) | HR (95% CI) |
|---|
Overall hazard ratios
|
5.2 ( 4.4-6.3)
|
18.8 (13.0-27.5)
|
7.1 (5.5-9.2)
|
P-Value
c
|
<0.001
|
<0.001
|
<0.001
|
Effect measure modifiers
| | | |
Kidney disease | | | |
Yes | 3.8 (2.9-5.1) | ns | 3.9 (2.5- 6.4) |
No | 6.8 (5.4-8.7) | ns | 10.2 (7.5-14.0) |
P-Value | 0.003 | 0.432 | <0.001 |
Sex | | | |
F | ns | ns | 3.4 (2.1- 5.6) |
M | ns | ns | 11.5 (8.4-15.7) |
P-Value | 0.818 | 0.239 | <0.001 |
-
aAll models adjusted for atherosclerosis, kidney disease, and sex. Hazard ratios compared the risk of a VTE in the 12 months after diagnosis for those with versus without a recent history of the specific VTE of interest. Results from SEER-Medicare Data (1991–2003).
-
bDVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
-
cP-Value for the difference between stratum specific estimates.
- ns = no statistically significant difference between strata.
